Find better answers from a bigger perspective in PET/CT imaging
Biograph Vision Quadra PET/CT
Bigger perspective. Better answers.
The power of a proven platform. The perspective of a large axial PET field of view. Biograph Vision Quadra™ takes the potential of PET/CT even further. Dynamically see vertex to thighs in a single position and deepen the dimension of your investigations. Whether you’re exploring new research questions or identifying the best clinical approach, with Biograph Vision Quadra, the answers are yours to find.
Bigger perspective. Better answers.
Engineered for new research dimensions
With best-in-class time-of-flight performance and
PET effective sensitivity1
1 Based on competitive literature available at time of publication. Data on file.
2 Compared to Biograph mCT. Measured value, based on phantom studies performed on a single system. Biograph Vision Quadra has a x32 gain based on acceptance values. Data on file.
Images acquired on Biograph Vision PET/CT.
Engineered for new research dimensions
A whole-body scanner that scans virtually all patients3 vertex to thighs
- Capture multiple organs simultaneously in a single field of view
- Dynamically follow tracer kinetics throughout the body
- Encompass the critical organs most evaluated in molecular imaging studies
3 Patient weight limit is 207 kg (500 lb)
Developed to reshape clinical outcomes
Leveraging a high-performing detector along with the vision of expanding capabilities
- Reducing crystal size improves spatial resolution and contrast recovery, thus improving detectability
- SiPMs cover 100% of the LSO array, maximizing the detection of light from the scintillator
- 100% coverage, enabling fast temporal resolution4
Developed to reshape clinical outcomes
A complete redesign of the PET detector to improve:
- Accuracy
- Performance
- Reproducibility
Biograph Vision Quadra™ delivers proven clinical outcomes of Biograph Vision™ at a greater scale.
Designed for your realities
The first whole-body PET/CT scanner, built for the same space as a traditional PET/CT scanner.
Our innovative architecture is designed for,
- Easy serviceability
- Efficient data management
- Enhanced workflows
Designed for your realities
With Biograph Vision Quadra™, you have a research and clinical solution designed for your realities.
User has ease of accessibility to the patient with,
- Large 78 cm bore
- Access to controls from both the front and rear of the gantry
- Positioning flexibility
Built to advance your vision
The next generation whole-body PET/CT scanner is here to help you lead the way in clinical and translational research, pioneering therapies, developing breakthrough procedures, and facilitating novel diagnostics.
“If we can really demonstrate that we can do something different and we can push the research clinical and pharmaceutical research forward, it will be a great satisfaction.”
Maurizio Conti, PhD
Director of PET Physics and Reconstruction, Siemens Healthineers
“What’s going to be exciting, is what the customers are going to do with it, what kind of knowledge is going to be acquired.”
Bernard Bendriem, PhD
Principle Research and Development Expert, Siemens Healthineers
“Right now, I think the main value of the Biograph Vision Quadra™ is potentially opening up new fields to what we could potentially see. We can only dream about. Now we have this device, and we can put it in the field and see it work.”
William Curtis Howe, MD
PET Product Manager, Siemens Healthineers
Whether you’re exploring new research questions or identifying the best clinical approach, with Biograph Vision Quadra™, the answers are yours to find.
Biograph Vision Quadra PET/CT
Data courtesy of Inselspital, Bern, Switzerland
- Malignant melanoma
- 90-min uptake
- 172 cm (5’6”)
- 105 kg (231 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 4i5s
Scan time
2 bed position / 4 min per bed
8 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
11 mCi (409 MBq)
CT
Scan parameters
100 kV/6 ref mAs
[a] See links below for Indications and Important Safety Information for Fludeoxyglucose F 18 (18F FDG) Injection.
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
- Lung cancer
- 110-minute uptake
- 175 cm (5’7”)
- 57 kg (126 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 4i5s
Scan time
1 bed position / 4 min per bed
4 min total scan time
1 bed position / 10 min
10 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
5.7 mCi (210 MBq)
CT
Scan parameters
100 kV/6 ref mAs
[a] See links below for Indications and Important Safety Information for Fludeoxyglucose F 18 (18F FDG) Injection.
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
- Diffuse large B-cell lymphoma
- 90-minute uptake
- 160 cm (5’2”)
- 57 kg (126 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 4i5s
Gaussian filter 2
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
5.1 mCi (191 MBq)
CT
Scan parameters
100 kV/6 ref mAs
[a] See links below for Indications and Important Safety Information for Fludeoxyglucose F 18 (18F FDG) Injection.
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
- Prostate cancer
- 166-minute uptake
- 185 cm (6’1”)
- 80 kg (176 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 4i5s
Gaussian filter 2
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
18F PSMA[a]
6.7 mCi (249 MBq)
CT
Scan parameters
100 kV/6 ref mAs
[a] The tracer used in this case is a research pharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in other countries worldwide. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
- Neuroendocrine tumor
- 78-minute uptake
- 172 cm (5’6”)
- 68 kg (150 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 4i5s
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
68Ga DOTATATE[a]
4.3 mCi (158 MBq)
CT
Scan parameters
120 kV/21 ref mAs
[a] The tracer used in this case is a research pharmaceutical. It is neither recognized to be safe and effective by the FDA nor commercially available in the United States or in other countries worldwide. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
Data courtesy of Inselspital, Bern, Switzerland
![Data courtesy of University Medical Center Groningen, Groningen, The Netherlands. [a] See slides 25-27 for Indications and Important Safety Information for Fludeoxyglucose F 18 (18F FDG) Injection.](https://cdn0.scrvt.com/7b8dc61d55f0deedb776692474194f7c/05e0ce3e92df18ee/6770ab869e96/v/50ef0ed74bd5/MI-5395-Slide-20.jpg?nowebp=1)
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Lymphoma
83-minute uptake
174 cm (5’7”)
68 kg (150 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 3i5s
All-Pass filter
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
5.5 mCi (205 MBq)
CT
Scan parameters
120 kV/5 ref mAs
83-minute uptake
174 cm (5’7”)
68 kg (150 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 3i5s
All-Pass filter
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
5.5 mCi (205 MBq)
CT
Scan parameters
120 kV/5 ref mAs
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
- Lymphoma
- 100-minute uptake
- 185 cm (6’1”)
- 82 kg (181 lb)
PET – Biograph Vision Quadra™
Scan acquisition
440 x 440 matrix, PSF+TOF 3i5s
All-Pass filter
Scan time
1 bed position / 10 min per bed
10 min total scan time
Injected dose
Fludeoxyglucose F 18 (18F FDG) Injection[a]
6.7 mCi (250 MBq)
CT
Scan parameters
100 kV/9 ref mAs
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Data courtesy of University Medical Center Groningen, Groningen, The Netherlands.
Indications and usage
Fludeoxyglucose F 18 injection is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizuresImportant safety information
Radiation Risk: Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.
Adverse Reactions: Hypersensitivity reactions with pruritus, edema and rash have
been reported; have emergency resuscitation equipment and personnel immediately available.Dosage forms and strengths
Multiple-dose 30 mL and 50 mL glass vial containing 0.74 to 7.40 GBq/mL (20 to 200 mCi/mL) of
Fludeoxyglucose F 18 injection and 4.5 mg of sodium chloride with 0.1 to 0.5% w/w ethanol as a stabilizer (approximately 15 to 50 mL volume) for intravenous administration.Fludeoxyglucose F 18 injection is manufactured by PETNET Solutions, a Siemens Healthineers Company,
810 Innovation Drive, Knoxville, TN 39732.
1
Biograph Vision Quadra is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.